Opinion|Videos|August 23, 2024
Choosing the Appropriate Treatment for Metastatic Uveal Melanoma
Author(s)Nathan L. Scott, M.D., Melody Burchett
Nathan L. Scott, M.D., provides a brief overview of the current guidelines for treatment of metastatic uveal melanoma, as well as what considerations go into choosing the appropriate treatment for it. This program was made possible with support from Immunocore.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Provide a brief overview of the current guidelines for the treatment of metastatic uveal melanoma.
- How has the approval of tebentafusp impacted the treatment landscape?
- How do you determine the right treatment for each patient?
- Provide a brief overview of the mechanism of action of tebentafusp. Which patients are eligible for this treatment?
- Why is it important for patients to know if they are HLA-A*02:01 positive?
- For patients not eligible for tebentafusp, what are your recommendations?
- As an advocate, how would you advise patients on how to approach selecting the best treatment option?
- What factors impact patients’ treatment selection, and what barriers do they face when selecting a treatment?
- How do you encourage patients to advocate for themselves when making decisions for their treatment?
- General query for these questions: Should they say the patient would work with their doctor to select best treatment for their situation?
Advertisement
Related to this article
A nurse practitioner discusses how an app provides information on cancer treatments, potential side effects and preparing for medical appointments.
Final KEYNOTE-564 data show Keytruda after kidney cancer surgery lowered the risk of death by 30%. Dr. Toni Choueiri explains what it means for patients.
HealthCare.gov open enrollment runs Nov. 1, 2026, to Jan. 15, 2027, and the 2027 out-of-pocket ceiling rises to $12,000. Here's what people with cancer should check before picking a plan.
After nearly a year of chemotherapy, a patient with stage 4 pancreatic cancer describes daily life and side effects on Rasonque (daraxonrasib).
For Lung Cancer Awareness Month, answers to common patient questions about biomarker testing in non-small cell lung cancer: which gene changes doctors look for, blood vs. tissue tests, insurance and retesting.
A physician emphasized how emotional support, reliable health information and caregiver involvement can encourage men to take a more proactive approach to prostate cancer screening and care.
After a blood cancer diagnosis, a survivor reflects on the close friends who let her be herself and asks whether she is the kind of friend she once needed.
From a new chemotherapy combination to the first RAS-targeted pill, here's what five years of pancreatic cancer approvals mean for patients.
Advertisement
Advertisement